Life science biotech company Cybin Inc. Cyban announced its selection of generalized anxiety disorder (GAD) with or without major depressive disorder (MDD) as a target indication for its proprietary deuterated DMT molecule, CYB004.
Anxiety disorders are the most common mental health concern in the US, with over 40 million adults (19.1% of the total population) suffering from one.
especially, To roam around Anxiety is a condition in which excessive anxiety and stress are present unrestrictedly under any specific environmental conditions. It currently affects 6.8 million US adults (3.1% of the total population), including females. twice Likely to be affected by GAD.
A 2022 GAD Therapeutic Market report good found that the economic burden of the condition is expected to increase to $12 billion by 2030.
“Nearly half of people with depression are also burdened by GAD, which makes the need for more effective treatment options for GAD all the more urgent,” said Cybin’s CEO. Doug Drysdale, “Since the pandemic, the prevalence of depression and anxiety has increased significantly, and we are optimistic that through our current development programs, Cybin has the potential to provide innovative treatments to alleviate the mental suffering that continues to plague the world. Many people experience.”
Preclinical data from the new chemical unit of cybin showed promise in the treatment of anxiety disorders and we are currently conducting our first clinical trial evaluating IV administration to assess safety and dose optimization data for further clinical development for the treatment of GAD. -Undergoing in-human Phase 1 trials.
To date, ongoing clinical studies have not demonstrated clinically significant safety or tolerability issues. The company is expected to provide an update on the CYB004 program by the end of February 2023.
Cybin acquired a US combination of matter patent covering the compound in February 2022.